Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.
Merchant M, Ma X, Maun HR, Zheng Z, Peng J, Romero M, Huang A, Yang NY, Nishimura M, Greve J, Santell L, Zhang YW, Su Y, Kaufman DW, Billeci KL, Mai E, Moffat B, Lim A, Duenas ET, Phillips HS, Xiang H, Young JC, Vande Woude GF, Dennis MS, Reilly DE, Schwall RH, Starovasnik MA, Lazarus RA, Yansura DG.
Merchant M, et al. Among authors: starovasnik ma.
Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):E2987-96. doi: 10.1073/pnas.1302725110. Epub 2013 Jul 23.
Proc Natl Acad Sci U S A. 2013.
PMID: 23882082
Free PMC article.